Science translational medicineAsthmaAnimalsAntibodiesMonoclonalHumanized
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma.
Seblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, Sivan Harel, Kaitlyn Gayvert, Dylan Birchard, Matthew F Wipperman, Dave Singh, Andrea T Hooper, George Scott, Julie E Horowitz, Jonas S Erjefält, Caroline Sanden, Kirsten Nagashima, Brianna Buonagurio
Published: 202510.1126/scitranslmed.adu3759
Abstract
Biologics targeting interleukin-4 receptor subunit α (IL-4Rα) and interleukin-33 (IL-33) have demonstrated clinical efficacy in asthma, highlighting the importance of IL-4, IL-13, and IL-33 in respiratory diseases. Despite this, few studies have link…
Preview only. Read the full abstract at the source